AbCellera Biologics (ABCL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed judgment of validity of its US patent 10,087,408, which is directed to microfluidic devices used for culturing and selectively recovering cells.
The patent was challenged by Bruker Cellular Analysis, a subsidiary of Bruker (BRKR), which alleged invalidity based on "anticipation and obviousness over the prior art," the company said. However, Bruker's arguments were rejected by the US Patent Trial and Appeal Board.
AbCellera's patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the US District Court for the Northern District of California.
Bruker didn't immediately respond to a request for comment from MT Newswires.
Price: 2.07, Change: +0.04, Percent Change: +1.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.